This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

ICD-10 G30.1 — Alzheimer disease with late onset Special Copayment Reduction: V810

Alzheimer disease with late onset알츠하이머병, 만기 발병

Synonyms and related terms: Late-onset Alzheimer disease (LOAD), senile Alzheimer disease, Senile dementia of Alzheimer type

ICD-10 dual coding guidance
G30.1 is a dagger (†) code describing the underlying neurological disease (Alzheimer disease with late onset), and the accompanying dementia syndrome is additionally coded with the asterisk (*) code F00.1* (dementia in Alzheimer disease with late onset). On claims, enter them in the order G30.1† F00.1*, with G30.1† as the principal diagnosis.
Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Late-onset Alzheimer disease (LOAD) is Alzheimer disease with onset after age 65 and accounts for about 90-95% of all Alzheimer disease. The index case described by Alois Alzheimer in 1906-1907 was an early-onset case with onset at age 51, but after that Emil Kraepelin in 1910 distinguished dementia occurring in the elderly as the 'senile form of Alzheimer's disease,' which began the dichotomy based on age 65. In British and American neuropathology studies of the 1970s-1980s, it was shown that senile dementia and presenile Alzheimer disease share the same amyloid plaque and neurofibrillary tangle pathology, and they began to be recognized as a single disease regardless of age.

The identification in 1993 of the APOE ε4 allele as the strongest genetic risk factor for LOAD is a milestone in late-onset Alzheimer disease research. A study by Corder et al. reported that with increasing gene dose of APOE ε4, the risk of onset increased and the age of onset became earlier. Subsequently, large genome-wide association studies (GWAS) identified dozens of LOAD risk gene loci, including CLU, PICALM, CR1, BIN1, the MS4A cluster, CD33, and TREM2, which are associated with amyloid processing, immune regulation, synaptic function, and lipid metabolism pathways.

In the 2020s, the success of phase 3 clinical trials of lecanemab and donanemab demonstrated the feasibility of anti-amyloid therapy, which has become a historic turning point shifting the paradigm of early intervention in the Alzheimer continuum, including LOAD.

2. Causes

Late-onset Alzheimer disease (LOAD) is a multifactorial disease rather than one with a single cause, arising from a complex interaction of genetic predisposition and environmental and aging factors. The strongest genetic risk factor is the APOE ε4 allele; ε4 heterozygotes have about a 3-fold increased risk of developing AD and homozygotes about 8-12-fold, with earlier onset. However, APOE ε4 is not a deterministic gene, and ε4 homozygotes can also reach old age without developing AD.

Aging itself is the greatest risk factor, and prevalence roughly doubles every 5 years after age 65. Modifiable risk factors include hypertension, diabetes mellitus, dyslipidemia, obesity, smoking, physical inactivity, hearing impairment, depression, head trauma, social isolation, low educational level, and exposure to air pollution, and active management of these is expected to contribute to suppressing the development of AD. Coexistence (co-pathology) of Alzheimer disease and cerebrovascular disease is common, and managing cerebrovascular risk factors also helps prevent pure AD.

3. Genetics

The heritability of LOAD is estimated at about 58-79% in twin studies, meaning that genetic factors contribute substantially to LOAD onset. However, unlike familial EOAD (PSEN1/APP/PSEN2 variants), the genetic architecture of LOAD is understood as the combined action of many common variants. The APOE gene (19q13.32) has three major alleles, ε2, ε3, and ε4; ε3/ε3 is the most common genotype, with ε4 associated with increased risk and ε2 with decreased risk.

Major LOAD risk genes identified in GWAS-based studies include CLU (clusterin, apolipoprotein J), PICALM (phosphatidylinositol binding clathrin assembly protein), CR1 (complement receptor 1), BIN1 (bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), SORL1, and ABCA7. The TREM2 p.R47H variant has emerged as the second strongest LOAD risk factor after APOE ε4 as a single variant (about 2-3-fold increased risk) and is associated with the amyloid phagocytic function of microglia.

Through recent multifaceted genomic analyses, the polygenic risk score (PRS), which integrates the multiple genetic risks of LOAD, is being used in clinical research and as an adjunct tool for early diagnosis. However, its predictive power for individual clinical patients is still limited, and broad clinical application for general screening purposes requires ethical consideration.

4. General epidemiology

Late-onset Alzheimer disease (LOAD) is the most common cause of dementia in people aged 65 and older, accounting for about 60-70% of all dementia. According to the World Alzheimer Report (2023), the number of people living with dementia worldwide is about 55 million and is projected to reach 152 million by 2050. Prevalence rises steeply with age, about 2% at age 65, about 7% at age 75, and about 25-40% at age 85.

In Korea, as of 2022, about 920,000 dementia patients aged 65 and older (prevalence about 10.2%) are estimated, of whom Alzheimer disease accounts for about 75%. By sex, prevalence is higher in women, which is studied as attributable to a combination of factors including survival bias (longer lifespan), postmenopausal estrogen decline, and sex-differential effects of APOE ε4. The annual incidence of dementia is estimated at about 10 million worldwide.

As for the economic impact, dementia-related costs worldwide reached about 1.3 trillion US dollars (USD) as of 2019, with caregiving costs (including informal care) accounting for most. In Korea as well, the annual management cost per dementia patient reaches tens of millions of won, and the socioeconomic burden due to population aging continues to increase.

5. Pathophysiology

The pathophysiology of late-onset Alzheimer disease (LOAD) shares fundamentally the same amyloid-tau pathology as early-onset (EOAD), but there is evidence that in LOAD impaired Aβ clearance plays a more important role than increased Aβ production. Aβ clearance mechanisms in the brain include transport across the blood-brain barrier (BBB), cerebrospinal fluid circulation, the glymphatic system, phagocytosis by astrocytes and microglia, and degradation by proteases, and the efficiency of these mechanisms declines with aging.

APOE ε4, as a lipid carrier, regulates the cerebrovascular transport of Aβ and microglial phagocytosis, and the ε4 isoform is inferior to ε3 in these functions, so Aβ clearance is delayed. TREM2 is a microglial surface receptor that regulates the formation of reactive clustering of microglia around Aβ plaques (DAM, disease-associated microglia), and loss-of-function variants of TREM2 reduce the Aβ phagocytic capacity of microglia.

Aging-related mitochondrial dysfunction, accumulation of oxidative stress, impaired proteostasis, telomere shortening, and epigenetic changes contribute to the pathogenesis of LOAD. Cerebrovascular dysfunction (small vessel sclerosis, BBB damage, reduced cerebral blood flow) coexists with Alzheimer pathology and accelerates cognitive decline. Among neuroinflammatory mechanisms, chronic low-grade neuroinflammation has attracted attention as a promoting factor in LOAD progression, with NLRP3 inflammasome activation and complement system overactivation involved.

6. Symptoms

The initial symptom of late-onset Alzheimer disease (LOAD) is typically episodic memory impairment, with prominent impairment of encoding and delayed recall of recent events. This reflects early damage to the hippocampal-entorhinal circuit, and repeated questions, repeated conversations, forgetting appointments, and forgetting where objects were placed are reported as initial symptoms. Impaired temporal orientation (recent date, day of the week, year) appears early, and impaired spatial orientation (getting lost in unfamiliar environments) is added in later stages.

Language decline appears as difficulty naming, delayed word retrieval, and impaired semantic memory, and as the disease progresses, auditory language comprehension declines and sentence construction errors increase. Visuospatial decline appears as drawing copy errors, difficulty avoiding obstacles while walking, and reduced driving ability, reflecting parietal lobe involvement. Executive function decline appears as impaired performance of multistep tasks, difficulty planning, and reduced impulse control.

Among behavioral and psychological symptoms (BPSD), depression, anxiety, and apathy are common early, and delusions of theft (the belief that possessions have been stolen), delusions of spousal infidelity (Capgras syndrome), wandering, agitation, sleep-wake cycle disturbance, and sundowning become prominent from the middle stage onward. These BPSD are major causes of patient functional decline and caregiver burden, and nonpharmacological and pharmacological interventions are required.

7. Signs

In early late-onset Alzheimer disease, no obvious focal neurological deficit is usually observed on neurological examination. Neuropsychological testing shows decreased MMSE/MoCA scores, decreased delayed recall on the CERAD word list learning, decreased Boston Naming Test (BNT), and decreased semantic fluency, reflecting hippocampal-temporal lobe dysfunction. From the middle stage onward, primitive reflexes such as the grasp reflex and grimace reflex, gait disturbance, postural instability, and rigidity may appear.

In LOAD in particular, cortical sensory abnormalities (astereognosis, agraphesthesia), constructional apraxia, and ideomotor apraxia appear along with parietal lobe involvement, and these are directly linked to impaired performance of daily activities. Impaired object recognition (visual agnosia) and impaired face recognition (prosopagnosia) due to visuospatial decline are also sometimes observed. In the terminal stage, limb rigidity, flexion posture, dysphagia, incontinence, and pressure ulcers progress, raising the risk of general debilitation and secondary complications.

8. Screening

For screening of late-onset Alzheimer disease (LOAD), the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are the most widely used. The MMSE has a maximum of 30 points, and a score of 23 or lower (after correction for educational level) is used as the criterion for suspected cognitive impairment, but its sensitivity is low at the mild cognitive impairment (MCI) stage, so it often misses cases when used alone. The MoCA assesses 7 domains—visuospatial/executive function, naming, memory, attention, language, abstraction, and orientation—on a 26-point basis, and a score of 25 or lower is regarded as suspected cognitive impairment (applying Korean standardized norms).

Caregiver-report screening tools include the AD8, the KDSQ-C, and the global rating of the CDR (Clinical Dementia Rating). The CDR grades 6 domains—memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care—as 0 (normal), 0.5 (mild cognitive impairment), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia), and is the standard tool for determining dementia severity. The CERAD (Consortium to Establish a Registry for Alzheimer's Disease) neuropsychological test battery (CERAD-K) is a comprehensive neuropsychological assessment tool with Korean standardized norms, used for diagnosis and follow-up of Alzheimer disease.

For imaging screening, the visual rating scale of medial temporal lobe atrophy (MTA) on brain MRI (Scheltens scale) is conveniently used. An MTA score of 3 or higher (average of left and right) is associated with Alzheimer dementia, and 1.5-2.0 may be associated with MCI. Amyloid PET visualizes brain amyloid deposition; if positive it supports an Alzheimer etiology, and if negative other causes should be considered.

9. Diagnosis

The clinical diagnosis of late-onset Alzheimer disease (LOAD) is based on the 2011 NIA-AA criteria for Alzheimer dementia (McKhann et al.) and the 2018 NIA-AA research framework (A/T/N biomarker classification). Clinically, probable AD dementia applies when the criteria are met of (1) gradual cognitive decline of insidious onset, (2) clear worsening from the previous cognitive level, (3) memory impairment or non-memory cognitive impairment (language, visuospatial, executive function), (4) impairment of daily functioning, and (5) exclusion of other causes (cerebrovascular disease, dementia with Lewy bodies, frontotemporal dementia, depression, delirium, etc.).

In CSF biomarkers, a pattern of decreased Aβ42 (or decreased Aβ42/Aβ40 ratio), elevated p-tau181/217, and elevated total tau suggests Alzheimer pathology, and the CSF p-tau/Aβ42 ratio (or CSF AD index) improves diagnostic accuracy. Plasma biomarkers (plasma p-tau217, p-tau181, Aβ42/Aβ40 ratio, GFAP, NfL) have been introduced in clinical research and some clinical settings; in particular, plasma p-tau217 has high accuracy for predicting Alzheimer pathology (AUC about 0.90 or higher), and its clinical application is spreading after standardization.

Amyloid PET (18F-florbetapir, 18F-florbetaben, 18F-flutemetamol) and tau PET (18F-flortaucipir) enable visualization of brain amyloid and tau pathology during life and increase diagnostic confidence in uncertain clinical diagnoses. In the 2018 NIA-AA research framework, A+T+(N+) corresponds to a pathobiological diagnosis of Alzheimer disease on the Alzheimer continuum and applies regardless of the presence of clinical symptoms. On neuroimaging, FDG-PET shows a parietotemporal hypometabolism pattern, and MRI shows hippocampal-entorhinal atrophy.

10. Treatment

Symptomatic treatment of late-onset Alzheimer disease is based on cholinesterase inhibitors (AChEI: donepezil, rivastigmine, galantamine) and memantine. Donepezil is the only AChEI approved by the FDA for mild, moderate, and severe AD, and the standard regimen is 5 mg once daily (4 weeks) followed by a maintenance dose of 10 mg. In severe AD, dose escalation from 10 mg to 23 mg shows additional cognitive improvement. Memantine contributes to stabilizing cognitive and daily function in moderate to severe AD, and combination with an AChEI is recommended.

As disease-modifying therapy, anti-amyloid monoclonal antibodies have been introduced into clinical practice. Lecanemab (Leqembi) binds Aβ protofibrils and delayed clinical decline (by CDR-SB) by about 27% over 18 months in patients with early AD (MCI and mild dementia) in the CLARITY AD phase 3 trial. Donanemab binds plaque-specific Aβ and delayed clinical decline by about 22-35% in the TRAILBLAZER-ALZ2 trial. Both drugs are indicated in the early Alzheimer continuum (confirmation of A+ required, CDR 0.5-1 stage), and MRI follow-up for ARIA monitoring is essential.

As nonpharmacological treatment, cognitive stimulation therapy (CST), reminiscence therapy, music therapy, art therapy, and exercise therapy play a supportive role in maintaining quality of life, and occupational therapy contributes to maintaining the ability to perform activities of daily living. For BPSD management, nonpharmacological approaches (environmental modification, behavioral therapy, family education) are prioritized, and after risk assessment, low-dose SSRIs (for depression and anxiety) and atypical antipsychotics (for agitation and aggression) are used short term. In progressive dementia, planning for palliative care, end-of-life care decisions, and hospice referral is a key role of the multidisciplinary team.

11. Prognosis

Late-onset Alzheimer disease is an irreversible, progressive neurodegenerative disease, with a course averaging 8-12 years from symptom onset to death. The higher the age of onset, the more coexisting age-related diseases there are, which affects survival. The clinical course progresses stepwise through the mild cognitive impairment (MCI) stage (CDR 0.5), mild dementia (CDR 1), moderate dementia (CDR 2), and severe dementia (CDR 3), and the rate of transition between stages varies with APOE genotype, coexisting vascular pathology, and response to initial treatment.

The introduction of anti-amyloid agents (lecanemab, donanemab) has been shown to delay the rate of clinical decline in the early stage by about 25-35%, but their effect on long-term survival or final functional level requires further long-term follow-up studies. The causes of death are mainly aspiration pneumonia, urinary tract infection, and pressure ulcer-related sepsis, and death due to direct neurological damage is rare. Plasma NfL levels increase in proportion to the rate of neurodegeneration, and high baseline NfL is associated with rapid cognitive decline.

12. Prevention

The core strategy for preventing late-onset Alzheimer disease is comprehensive management of modifiable risk factors. The 2020 Lancet Commission on dementia prevention estimated that 12 modifiable risk factors (low education, hearing loss, hypertension, obesity, smoking, depression, physical inactivity, social isolation, diabetes, excessive alcohol consumption, head trauma, air pollution) contribute to about 40% of dementia worldwide. Evidence is accumulating that a considerable proportion of AD can be prevented or delayed through management of these risk factors.

The Finnish FINGER trial showed that multidomain intervention (dietary improvement, exercise, cognitive training, management of cardiovascular risk factors) significantly mitigated overall cognitive decline over 2 years, and the World-Wide FINGERS network based on it (including Korea) is conducting multinational replication studies. Regular aerobic exercise can improve cognitive reserve by maintaining hippocampal volume, increasing neurotrophic factor (BDNF), and improving cerebrovascular function. Results of prospective studies have been published suggesting that correction of hearing loss through use of hearing aids in midlife is associated with reduced dementia risk.

Under Korea's national dementia responsibility policy, early cognitive screening for those aged 60 and older, dementia registration and management, and community dementia prevention programs are operated through dementia relief centers nationwide. Integrated management of cardio-cerebrovascular risk factors (control of blood pressure, blood glucose, and cholesterol), smoking cessation, moderate drinking, regular exercise, and increased social participation are recommended for all middle-aged and older adults for AD prevention and brain health promotion.

13. References